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Abstract
Peripheral neuropathy is a significant co-morbidity for patients with diabetes and as early as
1969, metformin was linked to reductions in vitamin B12, leading to deficiency. Vitamin B12
deficiency causes increased levels of homocysteine and methylmalonyl-CoA which are toxic to
the nervous system and therefore can contribute to demyelination. This quality improvement
study aimed to optimize the management of peripheral neuropathy symptoms by implementing a
process to identify patients with clinical or subclinical vitamin B12 deficiency and initiating
replacement therapy. Adult patients presenting for a scheduled office visit with a diagnosis of
type two diabetes and are taking metformin or medications containing metformin were included
in the study. The Michigan Neuropathy Screening Instrument and the NC-stat DPNcheck was
used to evaluate symptoms of neuropathy, and serum vitamin B12 levels were used to evaluate
vitamin B12 status. The implementation of this process increased the identification of patients
with low vitamin B12, thereby reducing the risk of patients in the sample population from
developing peripheral neuropathy, reducing symptoms of peripheral neuropathy, or limiting the
progression of peripheral neuropathy symptoms. This, therefore, has the potential to improve the
quality of life for patients living with type two diabetes that are taking metformin.
Keywords: type two diabetes mellitus, peripheral neuropathy, metformin, vitamin B12
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Optimizing Peripheral Neuropathy Management Through Vitamin B12 Screening in
Adults With Type Two Diabetes Mellitus Taking Metformin
Metformin is the first-line treatment for patients diagnosed with type two diabetes.
According to the Centers for Disease Control and Prevention ([CDC], 2020) Americans living
with a diagnosis of prediabetes or diabetes type two is greater than 100 million. Many studies
have demonstrated an association between vitamin B12 deficiency and metformin therapy (Yang
et al., 2019). Vitamin B12 is a water-soluble vitamin that plays a key role in DNA synthesis,
hematopoiesis, and normal function of the peripheral nervous system (Zalaket et al., 2018).
Therefore, vitamin B12 deficiency can lead to peripheral neuropathy like that of diabetic
neuropathy, megaloblastic anemia, as well as cognitive and memory impairments (Zalaket et al.,
2018). According to Polavarapu and Hasbani (2017) homocysteine and methylmalonyl-CoA
accumulate in the body due to vitamin B12 deficiency and are toxic to the nervous system.
Polavarapu and Hasbani go on to state that the incorporation of abnormal fatty acids into myelin
is the result of dysfunctional adenosylcobalamin-dependant methylmalonyl-CoA mutase and
methionine synthase causing demyelination. Demyelination can affect the peripheral nerves, the
spinal cord, and the white matter of the brain with large-fiber sensory loss affecting the lower
extremities first (Polayarapu & Hasbani, 2017).
The mechanism by which metformin causes vitamin B12 malabsorption is unclear.
According to Akinlade et al. (2015) several potential mechanisms may influence vitamin B12
deficiency including alteration in small bowel motility, inactivation or inhibition of vitamin B12
absorption, alteration in interactions with cubilin endocytic receptors, or effects on the absorption
of vitamin B12-intrinsic factor complex in the terminal ileum related to calcium channels. Clinic
FM serves over 680 patients with a diagnosis of diabetes mellitus type two that are on metformin

OPTIMIZING PERIPHERAL NEUROPATHY MANAGEMENT

9

therapy or therapies that contain metformin. Clinic FM did not have a system in place to identify
and screen these patients for vitamin B12 deficiency.
Problem Statement
Patients receiving metformin therapy are at increased risk of developing vitamin B12
deficiency that can contribute to additional co-morbidities such as peripheral neuropathy. Clinic
FM did screen diabetic patients for symptoms of peripheral neuropathy during routine diabetic
foot exams with the use of monofilament. However, vitamin B12 screening was not part of the
process, and the processes to identify peripheral neuropathy needed to be more robust.
Knowledge of a link between metformin therapy and alterations in vitamin B12
absorption was discovered over 50 years ago; however, since then few placebo-controlled studies
have been conducted (Aroda et al., 2016). There have been many cross-sectional cohort studies
that have recommended routine vitamin B12 screening for patients taking metformin. A systemic
review with meta-analysis completed by Chapman et al. (2016) included twenty-five studies in
its review and four of those twenty-five were included in the meta-analysis. Chapman et al.
stated that metformin decreases vitamin B12 levels at a rate of 57 pmol/L every 6 weeks to 3
months, potentially leading to frank vitamin B12 deficiency. In a post hoc analysis of a
randomized control trial (Out et al., 2018) concluded that over time, decreases in vitamin B12
associated with metformin therapy can lead to tissue damage. Furthermore, the researchers stated
that metformin was associated with a small increase in a validated neuropathy score, and while
not significant, this may have been due to metformin’s neuroprotective qualities counteracting
the damaging effects of low vitamin B12 (Out et al., 2018). This is an important point as diabetic
neuropathy can cause great discomfort and increased comorbid risk to patients. Prevention or
early detection of vitamin B12 deficiency could reduce the risk for diabetic patients of
developing neuropathy and significantly impact their quality of life.

OPTIMIZING PERIPHERAL NEUROPATHY MANAGEMENT

10

Assessment
Clinic FM is one of two primary care clinic locations offered by the organization. Clinic
FM is located near the intersection of Potranco Road and Dugas Road between State Highways
151 and 1604. At the time of assessment, there were three providers, and organization
management was searching for a fourth provider for this location. The clinic hours of operation
are Monday through Friday from 8:00 a.m to 5:00 p.m. The staff included a practice
administrator and a practice manager that split time between the two clinics, two front office
personnel, three medical assistants, and a referral coordinator. A third-party lab phlebotomist was
on site to complete specimen collection. Day-to-day clinic operations ran smoothly with limited
wait times. Appointment time allocations were as follows: 15 min for follow up or sick visits and
30 min for physicals and new patients.
Clinic FM had a large diabetic population with over 680 patients being identified as
having diabetes mellitus type two and currently on metformin therapy or therapies containing
metformin in 2019. The organization did not have a process in place to screen this patient
population for vitamin B12 deficiency. The organization demonstrated pride in preventive care
and improving the patient’s quality of life. The owner of this organization was also a provider
and had one of the largest patient panels in the practice. The owner was involved in the day to
day operation and flow of the clinic as well as the continued satisfaction of other providers and
staff. The organization participated in a Merit-based Incentive Payment System with one of the
quality improvement programs being Diabetes Care Recognition. One of the quality metrics
within Diabetic Care Recognition is the diabetic foot exam which included a sensation
component to test neurologic function.
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Project Identification
Project Purpose
The purpose of this project was to optimize the management of peripheral neuropathy
through the implementation of a screening process targeting vitamin B12 levels and a more
robust assessment for peripheral neuropathy in patients with a diagnosis of type two diabetes
mellitus receiving metformin therapy or therapies containing metformin.
Project Objectives and Anticipated Outcomes
The first aim was to educate the providers and staff on the new screening process and
integrate an identification process into the organization's current electronic health record (EHR)
to alert providers and staff of specific patients that meet the criteria for screening. The first
objective was to increase the identification and screening of patients in the target population for
vitamin B12 deficiency by 75%. The second objective was to initiate treatment in 85% of those
patients with clinical or subclinical vitamin B12 deficiency. The third objective was to screen
75% of patients in the target population for peripheral neuropathy using the Michigan
Neuropathy Screening Instrument. The overarching goal of this improvement project was to
increase the identification of patients in the target population with clinical or subclinical vitamin
B12 deficiency and optimize the management of peripheral neuropathy symptoms by prescribing
replacement therapy.
Summary and Strength of Evidence
The evidence that supports the monitoring of vitamin B12 levels among patients with
type two diabetes consists mainly of cohort and cross-sectional studies with few randomized
control trials likely due to ethical concerns as metformin is first-line therapy for type two
diabetes mellitus. However, a post hoc analysis of a randomized control trial demonstrated a
need for vitamin B12 screening for patients taking metformin.
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According to the American Diabetes Association (ADA, 2020) providers should consider
monitoring vitamin B12 levels for patients who are taking metformin. Also, for patients with
diabetic peripheral neuropathy, vitamin B12 deficiency should be considered as a potential cause
(ADA, 2020). Most studies available recommend routine screening of vitamin B12 for diabetic
patients taking metformin. In a randomized placebo-control trial conducted over 4.3 years, De
Jager et al. (2010) concluded that long-term treatment with metformin increases the risk of
vitamin B12 deficiency and that regular measurement should be strongly considered because
vitamin B12 deficiency is preventable. Furthermore, Aroda et al. (2016) completed a secondary
analysis of the Diabetes Prevention Program and the Diabetes Prevention Program and Outcomes
Study and concluded that metformin was associated with lower vitamin B12 levels when
compared with placebo after 5 years and there was an association between low vitamin B12 and
neuropathy. Aroda et al. (2016) went on to recommend routine screening due to an increased risk
of vitamin B12 deficiency with long-term use of metformin.
Neuropathy is an early symptom of vitamin B12 deficiency that presents before
megaloblastic anemia, and while the anemia is reversible with supplementation, the neuropathy
may not be reversible in all patients (Zalaket et al., 2018). However, the evidence is not
consistent in saying that metformin and vitamin B12 deficiency are associated with peripheral
neuropathy. Osama et al. (2015) concluded that there was a significant correlation between
peripheral neuropathy and vitamin B12 and that supplementation could prevent the condition.
Out et al. (2018) reported that it may be difficult to determine if low vitamin B12 is the culprit of
peripheral neuropathy because metformin is also known to have neuroprotective properties by
lowering HgbA1c that may be counteracting the damaging effects of low vitamin B12. Similarly,
Alharbi et al. (2018) concluded that metformin was associated with vitamin B12 deficiency but
found no association with peripheral neuropathy. Conversely, Aroda et al. (2016) reported that
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the secondary analysis of the Diabetes Prevention Program study data revealed a higher
prevalence of peripheral neuropathy in the metformin-treated patients. Gupta et al. (2018)
concluded that there was an association between metformin and peripheral neuropathy and
recommended that patients receiving metformin treatment should be screened annually for
peripheral neuropathy.
Treatment specifically for vitamin B12 deficiency related to metformin has not been
widely studied. Due to the hypothesized mechanism by which metformin affects the absorption
of vitamin B12, it would seem logical that the parental route of supplementation would be
preferred. However, according to Kancherla et al. (2016) patients who took a daily multivitamin
while on metformin had significantly higher vitamin B12 levels when compared to those who did
not take a daily multivitamin. This would suggest that the enteral route may be acceptable,
although this is only one study. Traditionally vitamin B12 replacement is accomplished by the
parental route, usually 1,000 µg IM injection daily or weekly to start and then monthly for
maintenance (Pawlak, 2017). Recently however, the oral route has begun to gain favor due to the
less-invasive nature; it is thought that oral supplements remain in the plasma for longer periods,
and there is a significant cost reduction when compared to the parental route (Pawlak, 2017).
Furthermore, according to Bauman et al. (2000) calcium supplementation can be used to reverse
the malabsorption of vitamin B12 caused by metformin.
Methods
Setting and Population
This quality improvement project was conducted in a suburban primary care clinic in the
city of San Antonio, Texas. The target population included adult patients with a diagnosis of
diabetes type two that were currently taking metformin or medication that contains metformin as
part of their treatment regimen.
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Intervention
The intervention began when a patient that was included in the target population entered
the clinic. When checking the patient in, the front office staff provided the patient with the
patient portion of the Michigan Neuropathy Screening Instrument (MNSI) and asked them to
complete the questionnaire. The questionnaire was given to patients at this time as to not cause a
delay in the normal workflow. The questionnaire was later collected and scored by the medical
assistant (MA) that brought the patient to the exam room; see Appendix A for copy of MNSI.
The MA then proceeded to complete the assessment portion of the neuropathy exam to include
the appearance of the feet, noting any deformities, fissures, dry skin or calluses, or signs of
infection. The MA also completed monofilament testing by applying the monofilament to 10
different locations on each foot with enough pressure to slightly bend the monofilament. The
patient having their eyes closed during this test was asked to respond yes when they felt the
monofilament touching their foot. The medical assistants at FM were previously trained to
execute a diabetic foot exam which included this portion of the neuropathy exam. The MAs were
also educated on the vibration sense exam using a 128 Hz tuning fork and how to test ankle
reflexes with a reflex hammer. Using the teach-back method the MAs were able to demonstrate
competence with these tests. The MAs then scored the responses to the monofilament test and
indicated normal sensation as at least eight out of ten correct responses, one to seven correct
responses meaning reduced sensation, and zero correct responses as absent sensation (University
of Michigan, 2000). MAs also tested vibration perception through the application of a 128 Hz
tuning fork to the distal interphalangeal joint of the right and left great toe. Vibration perception
was documented as normal if the vibration was sensed by the person administering the test for
less than 10 s after the patient no longer sensed the vibration, reduced if the person administering
the test sensed vibration for greater than or equal to 10 s after the patient no longer sensed the
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vibration, or absent if the patient reported no sensation of vibration during this test (University of
Michigan, 2000). Next, the MAs tested ankle reflexes and documented as present, present with
reinforcement if the Jendrassic maneuver was employed, or absent (University of Michigan,
2000); see Appendix B for instruction of MNSI use. The final component of the exam included
the application of the NC-stat DPNCheck device to the medial malleolus of the right or left ankle
and testing the velocity and amplitude of the electrical signals transmitted through the sural nerve
(NEUROMetrix, 2019). Normal results for the NC-stat DPNCheck were amplitude greater than 4
µV and velocity greater than 40 m/s, mild neuropathy results were amplitude greater than 4 µV
and velocity less than 40 m/s, moderate neuropathy results were amplitude less than 4 µV and
velocity greater than or less than 40 m/s, and severe neuropathy results were amplitude less than
4 µV and velocity less than 40 m/s (NEUROMetrix, 2019).
The providers then ordered lab tests and patients had blood samples collected by a
phlebotomist to evaluate their serum vitamin B12 levels. Patients with documented vitamin B12
deficiency or subclinical deficiency were prescribed treatment with oral vitamin B12
supplementation of 1,000 mcg and calcium 1,000 mg per day (Bauman et al., 2000; Schijns et
al., 2018).
Participants completed the patient version of the MNSI, and medical assistance
completed the physical exam portion during a regularly scheduled office visit. The total score
and individual questions for the patient version were quantified and the physical assessment
scores were quantified. A score greater than two on the physical assessment portion was
considered abnormal (Moghtaderia et al., 2006). Serum vitamin B12 levels were collected by
venipuncture with deficiency being defined as vitamin B12 less than 200 pg/ml and subclinical
deficiency being defined as vitamin B12 of 200-400 pg/ml.
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The MNSI was validated by Moghtaderia et al. (2006) who concluded that the MNSI is
an accurate and useful tool for diabetic neuropathy. The manufacture of NC-stat DPNcheck has
over 30 examples of validation that includes published studies, abstracts and posters, and a
conference presentation (NEUROMetrix, 2019).
Facilitators and Barriers
Clinic FM was well equipped with knowledgeable staff and motivations to provide highquality healthcare that improved the quality of life for patients. The clinic had a phlebotomist on
site which would increase the likelihood of compliance with blood collection for this study. The
equipment that was used for the intervention was readily available at clinic FM. The EHR
operating system used by the clinic for documentation was used to provide electronic
prescriptions directly to pharmacies. A request was made to the EHRs customer support to add a
quality measure that included vitamin B12 screening for patients in the target population to aid in
the identification and tracking. This request was denied and presented a barrier that was
overcome by manually flagging patients that met the criteria for inclusion in this new process.
Ethical Considerations
Patients who participated in the study were not recruited; participants included in the
target population that presented to the clinic for a previously scheduled office visit made up the
sample. During the office visit participants were subjected to venipuncture, however
venipuncture is minimally invasive and is part of the routine care for this population.
Participant’s privacy was protected by limiting patient identifiers. Regarding treatment, providers
employed shared decision making and education to allow for patient autonomy.
Results
This quality improvement initiative included N = 47 patients that had a diagnosis of
diabetes mellitus type two and were taking the drug metformin or medication with metformin in
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it. The implementation took place during the Spring of 2020 over 10 weeks. Table 1 summarizes
the demographics of the 47 participants that were seen in the clinic during the implementation
period.
Table 1
Summary Characteristics
Demographics

n

%

Hispanic

26

55.3

Non-Hispanic

6

12.8

Patient Declined

5

31.9

Male

15

31.9

Female

32

68.1

PPO/HMO

18

38.3

Medicare/Medicaid

11

23.4

Commercial

4

8.5

Other

14

29.8

Ethnicity

Gender

Payer Mix

Note. Total sample size (N = 47) with a mean age of 54.74 years old ranging from 34-76 years
old (SD = 10.8).
Patient questionnaires and the FMH flow chart were collected for review each week by the
Doctor of Nursing Practice (DNP) student. Also, Vitamin B12 results were collected from the
EHR weekly by the DNP student. Each intervention was completed at different rates with the
patient questionnaires being completed by 40 participants, Vitamin B12 results for 23
participants, and 16 participants were assessed using the NC-stat DPNCheck. Using a Pearson r,
negative relationships were demonstrated between vitamin B12 levels and the other assessment
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interventions. However no significant correlations were demonstrated between any of the
interventions. The most significant relationships were seen between vitamin B12 results and the
objective assessment (p = .061) as well as that between vitamin B12 and the patient
questionnaire (p = .09).
When analyzing vitamin B12 results (n = 23) the lowest result was 208 and the highest
was 876 with a mean of 489.13. Vitamin B12 results that were missing (n = 24) included ordered
testing that was not carried out by five participants and testing that was not ordered for 19
participants. Of the results, 39.1% were determined to be in the subclinical range and all

Figure 1
Vitamin B12 Results

Vitamin B12 Level (pg/ml)
Note. Clinical vitamin B12 deficiency was defined as <200 pg/ml while subclinical deficiency
was defined as 200-400 pg/ml.
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participants with subclinical vitamin B12 deficiency exhibited signs and symptoms of
neuropathy based on their responses on the patient questionnaire and the findings of the objective
assessment. Participants with vitamin B12 results in the clinical or subclinical range received
treatment at a rate of 100%. See Figure 1 for a visual representation of the vitamin B12 results
collected during the 10-week implementation period. Analysis of the responses from the
Michigan Neuropathy Screening Instrument (Appendix A) (n = 40) demonstrated that 48.9% of
participants screened had signs and/or symptoms of neuropathy based on their responses to the
patient questionnaire and the findings of the objective assessment.
Discussion
The purpose of this initiative was to implement a new process to identify patients in the
target population that would benefit from the optimization of vitamin B12 levels. Optimization
of vitamin B12 levels would therefore reduce the risk of progression or the development of
symptoms. For the nine patients identified with subclinical vitamin B12 deficiency, this initiative
was a success. For the participants that received treatment for low vitamin B12 levels, the risk of
developing further symptoms of neuropathy related to vitamin B12 has been reduced.
Neuropathy is a well know comorbidity for patients with type two diabetes mellitus. The
Diabetes Guideline supports the monitoring of vitamin B12 for patients being treated with
metformin and more importantly for those with signs and symptoms of neuropathy. Previously
cited literature used to support this initiative reported that rates of vitamin B12 deficiency in the
target population as high as 30% (Aroda et al., 2016; Zalaket et al., 2018). While the results of
this project were not significant, it is worth noting that for the sample size, it did have a similar
rate of low vitamin B12 levels as previous studies.
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Limitations
Several limitations considerably affected the results of this quality initiative and its
effectiveness. Chief among them was the events surrounding the development of a nationwide
pandemic that greatly limited the ability for the process to continue in its entirety. At the onset of
the pandemic, clinic visits were transitioned to telemedicine only. This meant that the objective
assessment would no longer be possible. Furthermore, lab services were halted at the clinic and
lab testing was only ordered if necessary. This placed greater risk and responsibility on patients
that now were required to have labs collected at a separate location or not at all. The pandemic
also reduced the number of patients in the target population that scheduled a telemedicine
appointment reducing the sample size.
While the pandemic presented a great obstacle, the inability of the EHR to automatically
flag patients offered an opportunity for human error to reduce the number of patients that were
recognized as being in the target population. While the buy-in of the staff and the providers was
good, follow through with all interventions was limited. Also, the Michigan Neuropathy
Screening Instrument scoring was overly confusing with several inverse questions that frustrated
staff and discouraged its use.
Recommendations
For future applications of this process, there are four recommendations to improve and
support the maintenance of the interventions. First, having several automated or manual alerts
would assist in the consistency of patient identification. Furthermore, this would improve the
follow through with the various interventions included in the process.
Second, having the screening questionnaire integrated into the EHR with automated
scoring would reduce errors and confusion when scoring the Michigan Neuropathy Screening
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Instrument. This would also improve compliance among clinic staff and allow for more efficient
data collection.
Third, reducing the number of facilitators involved in the process would limit the
possibilities of miscommunication and improve its efficiency. Moreover, limiting the facilitators
would minimize errors and improve the effectiveness of the interventions.
Fourth, patient education was not included as an intervention and could have enhanced
the experience of the participants. While it was expected that providers would use shared
decision making with patients that qualified for treatment, written patient education would have
enhanced participants' knowledge about the problem and what they can do to improve their
health. This would also provide an avenue to increase patient-provider relationships and improve
compliance with recommendations.
Implications for Practice
Many clinics participate in pay-for-performance programs that offer incentives for
providing high-quality care. Clinic FM is no exception, with one of their pay-for-performance
metrics being diabetic care recognition. A metric within diabetic care recognition is diabetic foot
care and more specifically the loss of peripheral sensation. The interventions outlined above
provide a process to better identify and assess patients for peripheral neuropathy and identify a
potential contributing factor that can easily be treated. As rates of diabetes continue to increase,
so too will the prescribing of the medication metformin. This project has demonstrated that
patients treated with metformin can experience low vitamin B12 levels that may be contributing
to signs and symptoms of peripheral neuropathy.
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Appendix A
Michigan Neuropathy Screening Insstrument
MRN:

Patient Version
MICHIGAN NEUROPATHY SCREENING INSTRUMENT
Please take a few minutes to answer the following questions about the feeling in your legs
and feet. Check yes or no based on how you usually feel. Thank you.
1. Are you currently taking metformin?

Yes

No

2. Have you had your vitamin B12 level checked in the last year

Yes

No

3. Are your legs and/or feet numb?

Yes

No

4. Do you ever have any burning pain in your legs and/or feet?

Yes

No

5. Are your feet too sensitive to touch?

Yes

No

6. Do you get muscle cramps in your legs and/or feet?

Yes

No

7. Do you ever have any prickling feelings in your legs or feet?

Yes

No

8. Does it hurt when the bed covers touch your skin?

Yes

No

Yes

No

10. Have you ever had an open sore on your foot?

Yes

No

11. Has your doctor ever told you that you have diabetic neuropathy?

Yes

No

12. Do you feel weak all over most of the time?

Yes

No

13. Are your symptoms worse at night?

Yes

No

14. Do your legs hurt when you walk?

Yes

No

15. Are you able to sense your feet when you walk?

Yes

No

16. Is the skin on your feet so dry that it cracks open?

Yes

No

17. Have you ever had an amputation?

Yes

No

9. When you get into the tub or shower, are you able to tell the
hot water from the cold water?

Total:
A—
no“ response on items 9 and 15 counts as 1 point. Item #6 is a measure of impaired
circulation and item #12 is a measure of general asthenia and are not included in scoring.
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MRN:

MICHIGAN NEUROPATHY SCREENING INSTRUMENT
B. Physical Assessment (To be completed by health professional)
1.

Appearance of Feet
Right
a. Normal

0

Left
Yes

1 No

Normal

0

1 No

b. If no, check all that apply:

If no, check all that apply:

Deformities
Dry skin, callus
Infection
Fissure

Deformities
Dry skin, callus
Infection
Fissure

Other
specify:

Other
specify:
Right
Absent

2.

Yes

Ulceration

Ankle Reflexes

4.

Vibration
perception at
great toe

5.

Monofilament

Present

0

Present
3.

Left

0

Present
0

Normal
0

Signature:

MNSI, © University of Michigan, 2000

Absent

1

Present/
Reinforcement
0.5

Decreased
0.5

Reduced
0.5

Present

0

Absent
1

Absent
1

Absent
1

Present

1

Present/
Reinforcement

0

Present
0

Normal
0

Total Score

0.5

Decreased
0.5

Reduced
0.5

Absent
1

Absent
1

Absent
1

/10 Points
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Appendix B
Instructions for Michigan Neuropathy Screening Instrument

How to Use the Michigan Neuropathy Screening Instrument
History
The history questionnaire is self-administered by the patient. Responses are added to obtain the
total score. Responses of “yes” to items 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as one point.
A “no” response on items 7 and 13 counts as 1 point. Item #4 is a measure of impaired circulation
and item #10 is a measure of general asthenia and is not included in the scoring. To decrease the
potential for bias, all scoring information has been eliminated from the patient version.
Physical Assessment
For all assessments, the foot should be warm (>30°C).
Foot Inspection: The feet are inspected for evidence of excessively dry skin, callus formation,
fissures, frank ulceration, or deformities. Deformities include flat feet, hammertoes, overlapping
toes, hallux valgus, joint subluxation, prominent metatarsal heads, medial convexity (Charcot
foot), and amputation.
Vibration Sensation: Vibration sensation should be performed with the great toe unsupported.
Vibration sensation will be tested bilaterally using a 128 Hz tuning fork placed over the dorsum of
the great toe on the boney prominence of the DIP joint. Patients, whose eyes are closed, will be
asked to indicate when they can no longer sense the vibration from the vibrating tuning fork.
In general, the examiner should be able to feel the vibration from the hand-held tuning fork for 5
seconds longer on his distal forefinger than a normal subject can at the great toe (e.g. examiner’s
DIP joint of the first finger versus patient’s toe). If the examiner feels vibration for 10 or more
seconds on his or her finger, then vibration is considered decreased. A trial should be given when
the tuning fork is not vibrating to be certain that the patient is responding to vibration and not
pressure or some other clue. Vibration is scored as 1) present if the examiner senses the vibration
on his or her finger for < 10 seconds, 2) reduced if sensed for ≥ 10 or 3) absent (no vibration
detection.)
Muscle Stretch Reflexes: The ankle reflexes will be examined using an appropriate reflex hammer
(e.g. Trommer or Queen square). The ankle reflexes should be elicited in the sitting position with
the foot dependent and the patient relaxed. For the reflex, the foot should be passively positioned
and the foot dorsiflexed slightly to obtain optimal stretch of the muscle. The Achilles tendon
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should be percussed directly. If the reflex is obtained, it is graded as present. If the reflex is absent,
the patient is asked to perform the Jendrassic maneuver (i.e., hooking the fingers together and
pulling). Reflexes elicited with the Jendrassic maneuver alone are designated “present with
reinforcement.” If the reflex is absent, even in the face of the Jendrassic maneuver, the reflex is
considered absent.
Monofilament Testing: For this examination, it is important that the patient’s foot is supported
(i.e., allow the sole of the foot to rest on a flat, warm surface). The filament should initially be
prestressed (4-6 perpendicular applications to the dorsum of the examiner’s first finger). The
filament is then applied to the dorsum of the great toe midway between the nail fold and the DIP
joint. Do not hold the toe directly. The filament is applied perpendicularly and briefly, (<1 second)
with even pressure. When the filament bends, the force of 10 grams has been applied. The patient,
whose eyes are closed, is asked to respond yes if he/she feels the filament. Eight correct responses
out of 10 applications are considered normal: one to seven correct responses indicates reduced
sensation and no correct answers indicate absent sensation.
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Appendix C
Clinic Flow Chart
Vitamin B12 Screening
Inclusion criteria: Adult patient with Dx of Diabetes Mellitus type 2 and is taking metformin.
Front desk - Patient to complete neuropathy questionnaire at check in
§

Questionnaire to be collected and scored by a medical assistant.

•

Total score:___________

Medical Assistant - complete diabetic foot exam to include:
o Appearance of feet
o Ulceration
o Monofilament
§

With patient’s eyes closed, ask patient to respond yes if he/she feels the filament.

§

Eight correct responses out of 10 is “normal”: one to seven responses indicate
“reduced” sensation: no correct responses indicates “absent” sensation.

o Ankle reflexes
§

If reflex is absent examiner can ask the patient to perform the Jendrassic maneuver.

§

If reflex is elicited with maneuver document “present with reinforcement”, if not
document reflex as “absent”.

o Vibration perception at great toe with 128 Hz tuning fork
§

Present if examiner feels vibration for < 10 seconds longer than the patient.

§

Decreased if examiner feels vibration for ≥ 10 seconds longer than the patient.

§

Absent if no vibration is sensed by the patient.

o Sural nerve conduction test using DPNCheck

•

Total score:___________

•

DPNC result: Amp-______

Provider – Review and sign Michigan Neuropathy Screening Instrument scoring.

Vel-_______

Provider - order serum vitamin B12 true
Provider - interpret lab results and prescribe treatment if indicated
§

Vitamin B12 result: ____________________

o If vitamin B12 deficiency (< 200 pg/ml) or subclinical deficiency (200-400 pg/ml) is identified
treat with vitamin B12 supplementation of 1,000 mcg and calcium supplementation of 1,000
mg per day.

